scispace - formally typeset
Search or ask a question
Institution

University of Münster

EducationMünster, Germany
About: University of Münster is a education organization based out in Münster, Germany. It is known for research contribution in the topics: Population & Transplantation. The organization has 35609 authors who have published 69059 publications receiving 2278534 citations. The organization is also known as: University of Munster & University of Muenster.


Papers
More filters
Journal ArticleDOI
TL;DR: This review focuses on the multidirectional impact of low testosterone associated with obesity and the metabolic syndrome and its effects on erectile dysfunction and CVD risk in men with type 2 diabetes.
Abstract: Men with obesity, the metabolic syndrome, and type 2 diabetes have low total and free testosterone and low sex hormone–binding globulin (SHBG). Conversely, the presence of low testosterone and/or SHBG predicts the development of metabolic syndrome and type 2 diabetes. Visceral adiposity present in men with low testosterone, the metabolic syndrome, and/or type 2 diabetes acts through proinflammatory factors. These inflammatory markers contribute to vascular endothelial dysfunction with adverse sequelae such as increased cardiovascular disease (CVD) risk and erectile dysfunction. This review focuses on the multidirectional impact of low testosterone associated with obesity and the metabolic syndrome and its effects on erectile dysfunction and CVD risk in men with type 2 diabetes. Whenever possible in this review, we will cite recent reports (after 2005) and meta-analyses. ### Epidemiological studies of low testosterone, obesity, metabolic status, and erectile dysfunction Epidemiological studies support a bidirectional relationship between serum testosterone and obesity as well as between testosterone and the metabolic syndrome. Low serum total testosterone predicts the development of central obesity and accumulation of intra-abdominal fat (1–3). Also, low total and free testosterone and SHBG levels are associated with an increased risk of developing the metabolic syndrome, independent of age and obesity (1–3). Lowering serum T levels in older men with prostate cancer treated with androgen deprivation therapy increases body fat mass (4). Conversely, high BMI, central adiposity, and the metabolic syndrome are associated with and predict low serum total and to a lesser extent free testosterone and SHBG levels (1–3,5). Because obesity suppresses SHBG and as a result total testosterone concentrations, alterations in SHBG confound the relationship between testosterone and obesity. Low total testosterone or SHBG levels are associated with type 2 diabetes, independent of age, race, obesity, and criteria for diagnosis of diabetes (6,7). In longitudinal studies, low serum total and free testosterone …

309 citations

Journal ArticleDOI
TL;DR: New insights are provided about the biochemical regulation, physiological functions and of newly identified target proteins of the major plant Ca2+ sensor families that enable specific, robust and flexible information processing in plants.

309 citations

Book ChapterDOI
01 Jan 2000
TL;DR: Versteht man unter „Routinelabor“ das Anforderungsprofil, das unabhangig von Anamnese und klinischem Befund bei jedem Patienten mit zunachst unbekannter Diagnose oder unbeknter Komplikation eines Patienten with bekannter diagnosis sinnvoll und notwendig ist, so sind vereinfacht zwei Situationen zu unterscheiden:
Abstract: Versteht man unter „Routinelabor“ das Anforderungsprofil, das unabhangig von Anamnese und klinischem Befund bei jedem Patienten mit zunachst unbekannter Diagnose oder unbekannter Komplikation eines Patienten mit bekannter Diagnose sinnvoll und notwendig ist, so sind vereinfacht zwei Situationen zu unterscheiden:

309 citations

Journal ArticleDOI
TL;DR: The results indicate that the N200 primarily reflects conflict-related effects whereas the P300 predominantly represents motor inhibition.

309 citations

Journal ArticleDOI
TL;DR: This trial provides the first high-level evidence base for selecting immunosuppression in LTx recipients with HCC and reveals that low-risk, rather than high- risk, patients benefited most from sirolimus; furthermore, younger recipients (age ⩽60) also benefited, as well siro Limus monotherapy patients.
Abstract: Background We investigated whether sirolimus-based immunosuppression improves outcomes in liver transplantation (LTx) candidates with hepatocellular carcinoma (HCC). Methods In a prospective-randomized open-label international trial, 525 LTx recipients with HCC initially receiving mammalian target of rapamycin inhibitor-free immunosuppression were randomized 4 to 6 weeks after transplantation into a group on mammalian target of rapamycin inhibitor-free immunosuppression (group A: 264 patients) or a group incorporating sirolimus (group B: 261). The primary endpoint was recurrence-free survival (RFS); intention-to-treat (ITT) analysis was conducted after 8 years. Overall survival (OS) was a secondary endpoint. Results Recurrence-free survival was 64.5% in group A and 70.2% in group B at study end, this difference was not significant (P = 0.28; hazard ratio [HR], 0.84; 95% confidence interval [95% CI], 0.62; 1.15). In a planned analysis of RFS rates at yearly intervals, group B showed better outcomes 3 years after transplantation (HR, 0.7; 95% CI, 0.48-1.00). Similarly, OS (P = 0.21; HR, 0.81; 95% CI, 0.58-1.13) was not statistically better in group B at study end, but yearly analyses showed improvement out to 5 years (HR, 0.7; 95% CI, 0.49-1.00). Interestingly, subgroup (Milan Criteria-based) analyses revealed that low-risk, rather than high-risk, patients benefited most from sirolimus; furthermore, younger recipients (age 60) also benefited, as well sirolimus monotherapy patients. Serious adverse event numbers were alike in groups A (860) and B (874). Conclusions Sirolimus in LTx recipients with HCC does not improve long-term RFS beyond 5 years. However, a RFS and OS benefit is evident in the first 3 to 5 years, especially in low-risk patients. This trial provides the first high-level evidence base for selecting immunosuppression in LTx recipients with HCC.

309 citations


Authors

Showing all 36075 results

NameH-indexPapersCitations
Hyun-Chul Kim1764076183227
Klaus Müllen1642125140748
Giacomo Bruno1581687124368
Anders M. Dale156823133891
Holger J. Schünemann141810113169
Joachim Heinrich136130976887
Markus Merschmeyer132118884975
Klaus Ley12949557964
Robert W. Mahley12836360774
Robert J. Kurman12739760277
Bart Barlogie12677957803
Thomas Schwarz12370154560
Carlos Caldas12254773840
Klaus Weber12152460346
Andrey L. Rogach11757646820
Network Information
Related Institutions (5)
Ludwig Maximilian University of Munich
161.5K papers, 5.7M citations

96% related

University of Zurich
124K papers, 5.3M citations

96% related

University of Amsterdam
140.8K papers, 5.9M citations

95% related

University of Pittsburgh
201K papers, 9.6M citations

95% related

University of California, Irvine
113.6K papers, 5.5M citations

95% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
2023253
2022831
20213,683
20203,499
20193,236
20182,918